Acomplia

Acomplia was ordered over the internet resulting in the delivery of counterfeit Acomplia and imitation products. The tablets were… Expand

Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have… Expand

The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia… Expand

The cannabinoid and serotonin systems modulate feeding behavior in humans and laboratory animals. The present study assessed… Expand

Rimonabant (AcompliaTM, SR141716A), a cannabinoid CB1 receptor inverse agonist, has recently been approved for the treatment of… Expand

Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized… Expand

Rimonabant (SR141716, Acomplia) has been described as an antagonist/inverse agonist at the cannabinoid receptor type 1 (CB1). It… Expand

It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory… Expand

Over past centuries, Cannabis sativa (Delta(9)-tetrahydrocannabinol being the principal active ingredient) has been used… Expand

The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus… Expand